Ignite Creation Date:
2025-12-24 @ 6:31 PM
Ignite Modification Date:
2026-01-05 @ 5:31 PM
Study NCT ID:
NCT04891757
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-10
First Post:
2021-05-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Sponsor:
Foghorn Therapeutics Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Hematologic Malignancy | View |
| None | Relapsed Acute Myeloid Leukemia | View |
| None | Refractory Acute Myeloid Leukemia | View |
| None | Relapsed Myelodysplastic Syndromes | View |
| None | Refractory Myelodysplastic Syndromes | View |
| None | Relapsed Chronic Myelomonocytic Leukemia | View |
| None | Refractory Chronic Myelomonocytic Leukemia | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | AML | View |
| None | Relapsed Acute Myeloid Leukemia | View |
| None | Refractory Acute Myeloid Leukemia | View |
| None | MDS | View |
| None | Relapsed Myelodysplastic Syndromes | View |
| None | Refractory Myelodysplastic Syndromes | View |
| None | Phase 1 | View |
| None | FHD-286 | View |
| None | Foghorn | View |
| None | CMML | View |
| None | Refractory Chronic Myelomonocytic Leukemia | View |
| None | Relapsed Chronic Myelomonocytic Leukemia | View |